The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular response and outcomes in patients with myeloproliferative neoplasms treated with interferon in the real-world setting.
 
Laneisha Maldonado Jaime
No Relationships to Disclose
 
Rachel Lazris
No Relationships to Disclose
 
Nikolas Papadantonakis
No Relationships to Disclose
 
Michael Hochman
Stock and Other Ownership Interests - Doximity
Honoraria - Fast4ward Learning; MJH Life Sciences; OncLive
Consulting or Advisory Role - Blueprint Medicines; Rigel
Research Funding - Daiichi Sankyo (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - Doximity; Rigel
 
Colin Vale
Consulting or Advisory Role - Geron; Syndax
 
David Frank
No Relationships to Disclose
 
Anthony Hunter
Honoraria - Blueprint Medicines; Pharmaessentia; Sobi
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb/Celgene; Cycle Therapeutics; Geron; GlaxoSmithKline; Incyte; Novartis; Pharmaessentia; Refined Oncology; SOBI
Research Funding - Ascentage Pharma (Inst); Blueprint Medicines (Inst); Cogent Biosciences (Inst); Disc Medicine (Inst); Incyte (Inst); Novartis (Inst); Pharmaessentia (Inst); Shenzen TargetRx (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Syntrix Biosystems (Inst); Telios (Inst)